The importance of imaging strategies for pre-clinical and clinical in vivo distribution of oncolytic viruses.

IF 6.7
Oncolytic Virotherapy Pub Date : 2018-03-28 eCollection Date: 2017-01-01 DOI:10.2147/OV.S137159
Adrian Pelin, Jiahu Wang, John Bell, Fabrice Le Boeuf
{"title":"The importance of imaging strategies for pre-clinical and clinical in vivo distribution of oncolytic viruses.","authors":"Adrian Pelin,&nbsp;Jiahu Wang,&nbsp;John Bell,&nbsp;Fabrice Le Boeuf","doi":"10.2147/OV.S137159","DOIUrl":null,"url":null,"abstract":"<p><p>Oncolytic viruses (OVs) are an emergent and unique therapy for cancer patients. Similar to chemo- and radiation therapy, OV can lyse (kill) cancer cell directly. In general, the advantages of OVs over other treatments are primarily: a higher safety profile (as shown by less adverse effects), ability to replicate, transgene(s) delivery, and stimulation of a host's immune system against cancer. The latter has prompted successful use of OVs with other immunotherapeutic strategies in a synergistic manner. In spite of extended testing in pre-clinical and clinical setting, using biologically derived therapeutics like virus always raises potential concerns about safety (replication at non-intended locations) and bio-availability of the product. Recent advent in in vivo imaging techniques dramatically improves the convenience of use, quality of pictures, and amount of information acquired. Easy assessing of safety/localization of the biotherapeutics like OVs became a new potential weapon in the physician's arsenal to improve treatment outcome. Given that OVs are typically replicating, in vivo imaging can also track virus replication and persistence as well as precisely mapping tumor tissues presence. This review discusses the importance of imaging in vivo in evaluating OV efficacy, as well as currently available tools and techniques.</p>","PeriodicalId":19491,"journal":{"name":"Oncolytic Virotherapy","volume":null,"pages":null},"PeriodicalIF":6.7000,"publicationDate":"2018-03-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2147/OV.S137159","citationCount":"7","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Oncolytic Virotherapy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2147/OV.S137159","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2017/1/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 7

Abstract

Oncolytic viruses (OVs) are an emergent and unique therapy for cancer patients. Similar to chemo- and radiation therapy, OV can lyse (kill) cancer cell directly. In general, the advantages of OVs over other treatments are primarily: a higher safety profile (as shown by less adverse effects), ability to replicate, transgene(s) delivery, and stimulation of a host's immune system against cancer. The latter has prompted successful use of OVs with other immunotherapeutic strategies in a synergistic manner. In spite of extended testing in pre-clinical and clinical setting, using biologically derived therapeutics like virus always raises potential concerns about safety (replication at non-intended locations) and bio-availability of the product. Recent advent in in vivo imaging techniques dramatically improves the convenience of use, quality of pictures, and amount of information acquired. Easy assessing of safety/localization of the biotherapeutics like OVs became a new potential weapon in the physician's arsenal to improve treatment outcome. Given that OVs are typically replicating, in vivo imaging can also track virus replication and persistence as well as precisely mapping tumor tissues presence. This review discusses the importance of imaging in vivo in evaluating OV efficacy, as well as currently available tools and techniques.

Abstract Image

Abstract Image

溶瘤病毒临床前和临床体内分布的成像策略的重要性。
溶瘤病毒(OVs)是一种针对癌症患者的新兴而独特的治疗方法。与化疗和放疗类似,OV可以直接杀伤癌细胞。总的来说,OVs相对于其他治疗方法的优势主要是:安全性更高(副作用更少)、复制能力强、转基因传递能力强、刺激宿主免疫系统抗癌。后者促使OVs与其他免疫治疗策略以协同方式成功使用。尽管在临床前和临床环境中进行了广泛的测试,但使用病毒等生物衍生疗法总是会引起对产品安全性(在非预期位置复制)和生物利用度的潜在担忧。最近出现的体内成像技术极大地提高了使用的便利性、图像的质量和获得的信息量。易于评估诸如OVs之类的生物治疗药物的安全性/本地化成为医生改善治疗结果的新潜在武器。鉴于OVs通常是复制的,体内成像也可以跟踪病毒的复制和持久性,以及精确地绘制肿瘤组织的存在。这篇综述讨论了体内成像在评估OV疗效中的重要性,以及目前可用的工具和技术。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
审稿时长
16 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信